Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Unmeasured Osmoles: The Hidden Solutes Obscuring a Hyponatremia Evaluation.

Cureus·2024

Same author

Feasibility of Nurse-Facilitated Advance Care Planning Among Older Veterans in a Dialysis Unit and an Oncology Infusion Center.

Military medicine·2024

Same author

New solutions to old problems-metabolic acidosis in chronic kidney disease.

Annals of translational medicine·2020

Same author

Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease.

Nutrients·2020

Same author

Hemodynamic and Laboratory Changes during Incremental Transition from Twice to Thrice-Weekly Hemodialysis.

Cardiorenal medicine·2020

Same author

Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2019

Search research articles

Related Experiment Videos

A 90-year-old man with hyperphosphatemia.

Shachi Lovekar¹, Joline L T Chen

¹Department of Medicine, Boston University School of Medicine, MA, USA.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation

|October 19, 2010

Summary

This summary is machine-generated.

Pseudohyperphosphatemia, a false high phosphate level, can occur in monoclonal gammopathy due to assay interference. Awareness prevents unnecessary treatment with phosphate binders in these patients.

Related Experiment Videos

Area of Science:

Nephrology
Clinical Chemistry
Hematology

Background:

Hyperphosphatemia is common in kidney disease, but can also occur spuriously in patients with normal kidney function.
Monoclonal gammopathy can interfere with phosphate assays, leading to falsely elevated results.

Observation:

A case of pseudohyperphosphatemia was identified in a patient with monoclonal gammopathy.
Elevated paraprotein levels can interfere with phosphate measurement assays.
This interference leads to falsely elevated phosphate readings, mimicking true hyperphosphatemia.

Findings:

Paraprotein-associated pseudohyperphosphatemia is a recognized phenomenon.
The presence of paraproteins can cause colorimetric interference in phosphate assays.
Methods like ultrafiltration or deproteinization can correct these spurious results.

Implications:

Patients with spurious hyperphosphatemia should not receive phosphate binders.
Clinicians must be aware of paraprotein interference to avoid misdiagnosis and inappropriate treatment.
Recognizing pseudohyperphosphatemia prevents unnecessary interventions in patients with monoclonal gammopathy.